Business Context and Reporting Period
Immunocore Holdings Plc (IMCR) is a commercial-stage biotechnology company focused on developing immunomodulating medicines, primarily through its ImmTAX platform. The company's lead product, KIMMTRAK (tebentafusp), is approved for the treatment of unresectable or metastatic uveal melanoma in 38 countries. This report covers the quarterly period ended September 30, 2024 (Q3 2024), and the nine months ended September 30, 2024 (YTD 2024).
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $80.2 million | $64.9 million | $226.2 million | $179.3 million |
| Net Income (Loss) | $8.7 million | $0.9 million | $(27.3) million | $(35.6) million |
| Operating Loss | $(8.5) million | $(14.1) million | $(51.0) million | $(42.6) million |
| Net Cash Provided by Operating Activities | N/A | N/A | $40.0 million | $20.7 million |
| Cash, Cash Equivalents, and Marketable Securities | $901.3 million | N/A | $901.3 million | N/A |
| Total Debt (Principal) | $452.5 million | $50.0 million | $452.5 million | $50.0 million |
| Accumulated Deficit | $(772.0) million | $(724.9) million | $(772.0) million | $(724.9) million |
Note: Q3 2024 marked the company's first profitable quarter, driven by strong product revenue and significant non-operating income.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 23.7% in Q3 2024 and 26.2% YTD 2024 compared to the prior year periods. Product revenue from KIMMTRAK grew 28.1% in Q3 and 32.0% YTD, driven by increased volume in the United States and global expansion.
- Profitability: The company reported a net income of $8.7 million in Q3 2024, a significant improvement from the $0.9 million net income in Q3 2023. This was largely due to a $9.0 million gain in "Other income (expense), net" from unrealized gains on marketable securities and a $4.0 million foreign currency gain.
- Debt Structure: In February 2024, the company issued $402.5 million in 2.5% Convertible Senior Notes due 2030. Consequently, total interest-bearing debt increased from $50 million (Pharmakon loan only) at year-end 2023 to $452.5 million at September 30, 2024.
- Expense Increases: Research and Development (R&D) expenses increased 22.0% in Q3 and 36.7% YTD, primarily due to the initiation of the Phase 3 PRISM-MEL-301 trial for brenetafusp and continued investment in tebentafusp programs.
Guidance, Outlook, and Risks
- Clinical Progress: The company presented positive data for brenetafusp in ovarian cancer at ESMO 2024. Randomization for the ATOM Phase 3 trial (adjuvant uveal melanoma) is expected to start in Q4 2024. The company will not release initial data for brenetafusp in NSCLC in Q4 2024.
- Liquidity: Management expects existing cash, cash equivalents, and marketable securities ($901.3 million) combined with anticipated KIMMTRAK revenue to fund operations for at least 12 months from the filing date. The company intends to repay the $50 million Pharmakon loan in full by December 31, 2024.
- Key Risks:
- Revenue Deductions: Significant estimation uncertainty exists regarding rebates and chargebacks. A 20% change in these estimates could impact reported product revenue by approximately $23.6 million for the nine months ended September 30, 2024.
- Regulatory and Clinical: Risks include the ability to maintain regulatory approval for KIMMTRAK, obtain approvals for new indications, and the success of ongoing clinical trials.
- Market Acceptance: Future revenue depends on market acceptance, reimbursement rates, and the ability to compete with other therapies.
Investor Verification Checklist
- Debt Repayment Plan: Verify the company's ability to repay the $50 million Pharmakon loan by Q4 2024 as stated in management commentary.
- Revenue Accruals: Review the $133.6 million in accrued rebates, chargebacks, and returns, noting the $12.6 million increase in estimates during the period due to unresolved uncertainties.
- Non-Operating Income: Assess the sustainability of the Q3 net income, which was heavily influenced by $9.0 million in unrealized gains on marketable securities and foreign currency fluctuations.
- Clinical Milestones: Monitor the initiation of the ATOM Phase 3 trial and the timeline for brenetafusp data releases in NSCLC.
- Convertible Notes: Evaluate the dilution risk associated with the $402.5 million Convertible Senior Notes, which have an initial conversion price of $94.70 per ADS.